TC Biopharm rises on cancer therapeutic's shelf life approval in UK

TC Biopharm (Holdings)

13/09/2022 18:54

** U.S.-listed shares of biopharmaceutical co TC Biopharm
 TCBP.O  rise as much as 6.7% to 36 cents
    ** Regulatory body MHRA approves 18-month shelf life for
TCBP's blood cancer therapeutic product OmnImmune  urn:newsml:reuters.com:*:nPnbC9K8Ya
    ** Approval enables TC BioPharm to ship and store the frozen
therapy product at clinical sites for its trials in patients
with acute myeloid leukemia, a kind of blood cancer, and in
other trials

 (Reporting by Nandhini Srinivasan in Bengaluru)
 ((Nandhini.srinivasan@thomsonreuters.com))